KKR closes $5.89 billion Integer Holdings take-private as PE healthcare consolidation accelerates

KKR & Co. closed its $5.89 billion acquisition of Integer Holdings in August 2026, taking private the medical device manufacturer in the largest healthcare PE transaction of a month that saw global buyout activity contract sharply. The deal, announced earlier this year, positions KKR with immediate exposure to cardiac rhythm management and neuromodulation devices as regulatory tailwinds and demographic shifts make medical technology one of the few sectors where allocators can justify stretched multiples.

Integer manufactures components for pacemakers, neurostimulators, and orthopedic devices. Revenue for the trailing twelve months was approximately $1.6 billion with EBITDA margins in the mid-teens. KKR paid roughly 11x forward EBITDA, a premium to the sector median but defensible given Integer's embedded customer base among large medical OEMs and its FDA-cleared manufacturing footprint. The firm funded the transaction with $2.1 billion in equity and the remainder in leveraged debt arranged through JPMorgan and Bank of America. Debt-to-EBITDA at close was approximately 5.2x, on the higher end for healthcare but within tolerance given the recurring revenue profile.

The timing matters. August 2026 global PE deal volume fell 38% year-over-year as financing costs remained elevated and exit windows stayed narrow. Healthcare represented 29% of total PE capital deployed during the month, the highest sector weight in fourteen months, driven almost entirely by this transaction. That concentration reveals a broader reallocation: firms are pulling back from consumer discretionary and industrial buyouts while doubling into healthcare, where reimbursement visibility and aging demographics create a floor under valuations. KKR's move also signals confidence that the Federal Reserve's rate trajectory will support a refinancing or exit by late 2028, when Integer's debt matures and the firm will need to either syndicate or prepare an IPO.

Integer's customer concentration is both strength and constraint. Approximately 62% of revenue comes from the top ten medical device OEMs, including Medtronic and Abbott. That stickiness protects downside but limits pricing power. KKR will likely pursue margin expansion through procurement consolidation and automation of the manufacturing base in Guadalajara and Tijuana, where Integer operates 340,000 square feet of cleanroom capacity. The firm has a playbook here: its 2021 acquisition of Envision Healthcare involved similar operational tightening, though that deal faced reimbursement headwinds Integer is less exposed to.

Allocators should track three follow-on events. First, whether KKR brings in a co-investor or sells a minority stake to a sovereign wealth fund within the next six months to de-lever the balance sheet and extend hold period optionality. Second, any FDA 510(k) clearances for Integer's next-generation battery technology, expected in Q2 2027, which would materially improve gross margin and justify the entry multiple. Third, KKR's refinancing approach in mid-2028, which will reveal whether the firm sees this as a long-hold infrastructure-style asset or a traditional three-to-five-year flip.

The deal closed without material regulatory delay. That alone is the signal.